With First IND, Recursion Readies Its AI, Experimental Biology Approach For The Clinic

Emerging Company Profile: With an early focus on rare, monogenic diseases, Recursion believes its platform combining artificial intelligence and experimental biology can be applied to any disease that can be modeled on a cellular level.

Emerging Company Profile Regular column feature image Version 2

Based on its founder’s graduate work at the University of Utah, Recursion Pharmaceuticals LLC is repurposing existing molecules for rare monogenic diseases by using phenotypic screening that is optimized by artificial intelligence and the company intends to begin its first clinical trial before the end of 2018.

Having raised about $80m in venture funding to date, the Salt Lake City biotech recently obtained its first investigational new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.